Although RPL22L1 expression is induced in a compensatory manner in Rpl22−/− mice and can support translation (58), RPL22L1 plays a pivotal role in the malignancy of colorectal cancer (34), hepatocellular carcinoma (35), and prostate cancer (36). Here, RPL22 is linked to prostate carcinoma.